Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.69 |
| ▸ | SYK | P43405 | 5/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.61 |
| ▸ | PAK4 | O96013 | 3/20 | 0.61 |
| ▸ | PIM1 | P11309 | 3/20 | 0.61 |
| ▸ | PRKACA | P17612 | 3/20 | 0.61 |
| ▸ | CDK2 | P24941 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 3/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.61 |
| ▸ | CLK2 | P49760 | 3/20 | 0.61 |
| ▸ | CDK9 | P50750 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 3/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.61 |
| ▸ | STK3 | Q13188 | 3/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.61 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435114 | 0.89 | KDR (0.65) | KDRSYKDAPK3PRKD3MAP4K4 | |
| Hydrochloric Acid SCHEMBL6246305 | 0.88 | KDR (0.64) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL13867837 | 0.85 | KDR (0.80) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL3891347 | 0.83 | KDR (0.75) | KDRSYKDAPK3PRKD3MAP4K4 | |
| Hydrochloric Acid SCHEMBL3896569 | 0.82 | KDR (0.74) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL3890896 | 0.82 | KDR (1.00) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL13867811 | 0.82 | KDR (0.67) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL3903732 | 0.82 | KDR (0.73) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL4566509 | 0.81 | KDR (0.59) | KDRSYKDAPK3PRKD3MAP4K4 | |
| SCHEMBL187444 | 0.81 | KDR (0.72) | KDRSYKDAPK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7105682-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060194848-A1 | e.g. 2-(1H-indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide; angiogenesis inhibitors, antiproliferative or anticarcinogenic agents | AMGEN INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885SYK 678/4885DAPK3 2776/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885SYK 678/4885DAPK3 2776/4885 |
| US-20060194848-A1 | e.g. 2-(1H-indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide; angiogenesis inhibitors, antiproliferative or anticarcinogenic agents | NNT, NAMPT, NNMT | KDR 51/4885SYK 3136/4885DAPK3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.